A maker of handheld chemical detectors, 908 Devices builds tools like the MX908 that soldiers, hazmat teams, and police use to spot explosives, drugs such as fentanyl, and dangerous chemicals on the spot. Founded in Boston in 2012, the company shrank lab-grade mass spectrometry into a pocket-sized device. Its odd name comes from 0.908, the point in a mass spectrometer where founders say "the magic happens"—a fitting symbol for finding answers in unstable moments.
VipIR FTIR placements drove 23% revenue growth, but a $6.4M contingent consideration charge kept 908 Devices unprofitable.
Product rose on VipIR demand, but a U.S. defense customer paused MX908 service coverage. Revenue rose 23% to $16.1 million and product expanded 7 points to 51%, yet a $6.4 million non-cash charge drove a $12.8 million operating loss. The company remains unprofitable, with $101.5 million in cash and marketable securities funding operations for at least 12 months.
Key takeaways
rose 23% to $16.1 million, driven by a $2.6 million increase in FTIR product sales from VipIR placements, which lifted total product revenue 35% to $13.0 million.
Service and contract fell 10% to $3.1 million, primarily from a $0.7 million decline in MX908 extended service contracts as a U.S. defense customer paused coverage due to funding constraints.
Product expanded 7 percentage points to 51%, helped by higher volume, a shift away from lower-margin international sales, and reduced facility costs after the Boston site shutdown.
Section summaries
Management's Discussion and Analysis
Q2 FY2026 revenue rose 23% to $16.1M, driven by VipIR FTIR placements, while net loss narrowed to $11.9M.
⌄
Total rose 23% to $16.1M in Q2 FY2026, with product revenue up 35% to $13.0M, led by a $2.6M increase in FTIR products from VipIR placements.
Service and contract fell 10% to $3.1M, mainly due to a $0.7M decline in MX908 extended service contracts from a U.S. defense customer's funding-related pause.
A $6.4 million non-cash charge from an increase in the fair value of tied to the RedWave acquisition was the single largest expense, driving the $12.8 million operating loss.
swung to a $3.2 million inflow from a $5.8 million outflow a year ago, supported by non-cash charges and improvements.
Cash, cash equivalents, and marketable securities totaled $101.5 million at quarter-end, and management stated existing resources are sufficient to fund operations for at least 12 months.
What changed
The funding-related pause in MX908 service coverage by a U.S. defense customer, first flagged in Q1 FY2026, deepened: service and contract fell 10% this quarter after a 19% decline last quarter, confirming the pause is not yet resolved.
Product expanded to 51%, sustaining the 7-point improvement seen in Q1 FY2026, suggesting the benefit from reduced facility costs after the Boston shutdown and a favorable sales mix is holding.
The liability generated another $6.4 million in non-cash charges this quarter, bringing cumulative charges to $35.4 million, and continues to create earnings volatility as the company's share price fluctuates.
improved to a $3.2 million inflow, marking a second consecutive quarter of positive operating cash flow after the $1.2 million inflow in Q1 FY2026, a reversal from the $5.8 million outflow in the same quarter last year.
What to watch
Whether the U.S. defense customer's funding-related pause in MX908 service coverage resolves, as service and contract has now declined for two consecutive quarters.
Whether the liability continues to generate material non-cash charges, given that $12.8 million has been recorded in the first half of FY2026 and the liability is tied to the company's share price.
Whether product can hold above 50% now that the Boston site shutdown benefit has been absorbed, or if higher costs from VipIR production ramp compress margins.
Whether the company can sustain positive , which improved to a $3.2 million inflow this quarter, to extend the cash runway beyond the stated 12-month horizon.
Product improved 7 points to 51%, helped by higher volume, a shift away from lower-margin international sales, and lower facility costs after the Boston shutdown.
Operating expenses were nearly flat at $21.2M, but a $6.4M non-cash charge kept the company unprofitable.
Cash, cash equivalents, and marketable securities totaled $101.5M at June 30, 2026, and the company expects this to fund operations for at least 12 months.
For the six months, rose 19% to $29.5M, but net loss from continuing operations widened to $23.8M from $22.7M, driven by a $12.8M charge.
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act for this reporting period and are not required to provide the information required under this item.
⌄
We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act for this reporting period and are not required to provide the information required under this item.
Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the industry in which we operate as well as risks that affect businesses in general. In addition to the information…
⌄
Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the industry in which we operate as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 9, 2026. The risks and uncertainties disclosed in such Annual Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. There have been no material changes to our previously disclosed risk factors.
These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2,“Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.